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AN EXAMINATION OF THE EFFICACY OF CHRONOTHERAPEUTICS AS A 
TREATMENT FOR MOOD DISORDERS  
LISA RAMROOP 
ABSTRACT 
 The body is influenced by the earth’s day and night cycling. Various biological 
systems within the body have different activity and rest cycles during a 24-hour period. 
This is often referred to as the body’s circadian rhythm. The autonomic nervous system, 
cardiovascular system, hepatic and renal system, to name a few, all depend on the 
carefully calibrated timings of the body’s internal clock. Variations or abnormalities in 
this normal rhythm can lead to the development of an assortment of disease states and 
pathologies. One disease state that readily exemplifies the connection between disordered 
circadian rhythms and pathology is that of mood disorders like depression. There is a bi-
directionality in cause and effect; desynchronized circadian timing can contribute to the 
development of mood disorders, while certain symptoms present in mood disorders can 
create or exacerbate irregular circadian rhythms. Mood disorders are serious disease 
states and are the number one cause of disability worldwide. The conditions can often be 
chronic, recurrent and debilitating for their sufferers, leading to further health issues, loss 
of productivity and function in society and increasing the likelihood of death, either 
through corresponding health conditions or in some instances, suicide.  The number of 
people being diagnosed with mood disorders is increasing every year, and those who are 
aware of their status oftentimes are still suffering with symptoms. Various treatment 
options have been utilized, most commonly pharmacological therapy in the form of 
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prescription medications, or psychotherapy. However, these treatment options face 
limitations in efficacy, safety, and speed of action. Chronotherapeutics, or the use of 
external environmental stimuli to retrain the body’s biological clock, is being examined 
as a potential treatment for mood disorders. These chronotherapeutic treatments include 
sleep deprivation, bright light therapy, blue light blocking glasses and melatonin 
supplementation. Sleep deprivation has been shown to be helpful in treating the 
symptoms of major depressive disorder and bright light therapy alleviates symptoms of 
seasonal affective disorder, major depressive disorder and bipolar depression--even in 
vulnerable populations. Melatonin has shown usefulness in resetting circadian rhythms, 
while blue light blocking glasses accomplish the same, along with decreasing the severity 
of manic episodes in bipolar depression. A combination of chronotherapeutic approaches 
has proven the most effective of all, able to treat seasonal affective disorder, major 
depressive disorder and bipolar depression, with a longer lasting respite from symptoms 
and offering an alternative to those who have been previously non-respondent or resistant 
to other conventional treatment options. Lack of clinician knowledge about 
chronotherapeutic options, as well as limitations in the availability of chronotherapeutic 
devices in hospital settings currently limit accessibility to treatment. More research also 
needs to be done to further illuminate the mechanistic actions that underlie the body’s 
circadian timings. Chronotherapeutics proves itself as a useful tool in the battle against 
mood disorders and should be more readily utilized as a treatment option in the future. 	
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INTRODUCTION 
Body Clock Biology 
 The body’s biological processes are all carefully timed and executed, and the 
body’s circadian rhythm, or its internal biological signaling and timing, is important in 
maintaining a proper healthy and functioning body (Dopierala and Rybakowski, 2015). 
There are many cells and genes in the body that utilize circadian rhythms which are in 
tune with one another and with the earth’s solar cycles (Hastings et al., 2008).   
Growth hormone, melatonin, insulin, ghrelin, leptin and cortisol secretion all 
depend on the biological rhythms of the body, as do cellular metabolic cycles (McKenna 
et al., 2018) (Hastings et al., 2008). The body’s circadian rhythm also affects temperature 
regulation, the respiratory system, brain wave activity, the cardiovascular system 
including coagulation, and the functions of the immune system (McKenna et al., 2018). 
In the immune system, cytokines, interferon-𝛾, interleukin-6 (IL-6), 𝛽-defensin-1 and 
tumor necrosis factor-𝛼 (TNF-𝛼) all display circadian rhythmicity or are mediated by 
circadian genes (Chan et al., 2012). In the digestive system, the jejunum and Paneth crypt 
cells in the intestines possess pattern recognition receptors, which help identify foreign 
gastrointestinal bacteria, and these exhibit a circadian oscillation as well (Chan et al., 
2012). The cardiovascular system displays circadian rhythmicity in many ways. In the 
circulatory system, circulating platelet numbers are the highest in the afternoon, as are 
incidences of fatal strokes and sudden cardiac death (Chan et al., 2012). Meanwhile, 
aggregation ability, plasminogen activator inhibitor type 1 (a fibrinolysis regulator), 
lipoprotein a, and fibrinogen levels peak in the morning alongside a higher incidence of 
	 	
 2 
myocardial infarctions and strokes in the morning hours as well (Chan et al., 2012). The 
heart possesses genes that are also under circadian influence, and these genes serve to 
assist with cardiac remodeling, influencing heart rate, and fatty acid and oxygen 
utilization (Chan et al., 2012). The respiratory system is influenced by body clocks as 
well. Depending on the time of day, healthy people can display small variations in the 
volume of air exchanged per respiratory cycle, the volume of air released from the lungs 
every minute and the average volume of air delivered to the lungs every minute, 
regardless of the amount of activity they do every day (Chan et al., 2012). Additionally, 
surfactant protein D, which helps the body defend itself against inspired pathogens, made 
by alveolar epithelial type 2 cells and Clara cells in the lungs, also have a biological 
rhythmicity, with surfactant protein D levels reaching their apex at 10 a.m. and finding 
their lowest level by 10 p.m. (Chan et al., 2012). Hepatic and renal systems are other 
systems also affected by the body’s biological rhythms. As epinephrine and glucagon 
experience circadian influence, subsequently gluconeogenesis and glucose metabolism 
are also under circadian control (Chan et al., 2012). In the kidneys, the filtration rate of 
the glomerular apparatus, tubular and electrolyte secretion, tubular absorption, renal 
epithelial cell excretion, the amount of blood flow to the kidneys, and erythropoietin 
production all follow circadian rhythms (Chan et al., 2012).  
 
Generating a Circadian Rhythm 
Body tissues and genes that utilize circadian signaling do so via a complex pathway. In 
the body, circadian dependent cells work with the anterior hypothalamic suprachiasmatic 
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nuclei, cells which have an important governing role in regulating the body’s biological 
rhythms (Dopierala and Rybakowski, 2015) (Hastings et al., 2008). To begin the process, 
light primarily stimulates a photopigment called melanopsin, which is found in light 
sensitive ganglion cells (Oldham and Ciraulo, 2014) (Brown et al., 2018) (Dopierala and 
Rybakowski, 2015). Light also stimulates accessory neuronal pathways in the retina, 
which activate rod cells with rhodopsin or cone cells with photopsin, although these are 
not stimulated as strongly as the melanopsin cells (Oldham and Ciraulo, 2014). 
Combined, this stimulation turns on the nonimage-forming (NIF) intrinsically 
photosensitive retinal ganglion cells (ipRGCs) (Oldham and Ciraulo, 2014). The 
melanopsin photopigments have the greatest reaction when stimulated by the blue light 
portion of the Ultraviolet (UV) spectrum, which involves wavelengths of between 400-
530 nm, but the ancillary stimulation of the other rods and cones surrounding the area 
help activate the pathway in people who lack sufficient melanopsin, either in sufficient 
density or completely (Oldham and Ciraulo, 2014) (Brown et al., 2018). The ipRGCs 
transfer the message to the suprachiasmatic nuclei via the retino-hypothalamic tract 
(Oldham and Ciraulo, 2014) (Brown et al., 2018) (Dopierala and Rybakowski, 2015). 
Figure 1 shows other brain nuclei stimulated by the ipRGC’s. This light dependent 
stimulation of the suprachiasmatic nuclei in particular helps align earth’s day and night 
cycles to the body’s circadian rhythms (Oldham and Ciraulo, 2014) (Brown et al., 2018) 
(Dopierala and Rybakowski, 2015). The suprachiasmatic nuclei also work with the locus 
coerulus in the brainstem to manage noradrenergic neurons, another component which 
helps control the body’s desire to go to sleep or wake up (Dopierala and Rybakowski, 
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2015). Research has found that the pre-optic and dorsomedial hypothalamus seem to be 
primarily in control of the body’s sleep and wake cycle (Hastings et al., 2008). In 
addition to the locus coerulus, the suprachiasmatic nuclei send signals to the pineal gland, 
assisting in the regulation of melatonin secretion (Dopierala and Rybakowski, 2015). For 
this function, the suprachiasmatic nuclei send projections to the paraventricular nucleus 
of the hypothalamus, which then propagates the signal to the medial forebrain bundle, 
onward to the spinal cord, then to the superior cervical ganglion and finally the signal 
terminates at the pineal gland where melatonin is then released (Oldham and Ciraulo, 
2014). The suprachiasmatic nuclei also contain specific receptors for melatonin, whereby 
the hormone works to cause shifts or further regulation of biological rhythms (Dopierala 
and Rybakowski, 2015). If the suprachiasmatic nuclei are destroyed, there is no sleep-
wake rhythm and if the nuclei are restored, the rhythm returns, showing the direct 
connection between circadian oscillations and the suprachiasmatic nuclei in animal 
models (Lévi, 2006). Vasoactive intestinal peptide (VIP), cardiotrophin-like cytokine and 
prokineticin 2 and their receptors, among others, assist with sending signals from the 
suprachiasmatic nuclei to targets located elsewhere in the brain (Hastings et al., 2008). 
These neuropeptides are also regulated by the body’s circadian rhythm (Hastings et al., 
2008). The suprachiasmatic nuclei also act as a “circadian pacemaker” of sorts, although 
it is not the only one in the body. The circadian genes that express themselves in 
peripheral tissue imitate the genes expressed in the suprachiasmatic nuclei, but there is 
often a delay in time (Hastings et al., 2008). Subsequent research has found that even 
without the suprachiasmatic nuclei, circadian dependent gene expression in many major 
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organ systems can operate independently. Within cells, circadian rhythmicity can also be 
independently maintained on the molecular level (Hastings et al., 2008). Fibroblasts 
especially seem to maintain the circadian rhythm independently, even when separated 
form the suprachiasmatic nuclei influence (Hastings et al., 2008). Generally, because of 
the connection to the retina, the suprachiasmatic nuclei help harmonize, synchronize and 
maintain these various body system clocks with one another via hormones and neuron 
impulses and in conjunction with the solar cycle (Hastings et al., 2008) (McKenna et al., 
2018). Melatonin also plays a role in helping synchronize the peripheral tissues along 
with the suprachiasmatic nuclei (McKenna et al., 2018). 
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Figure 1. Stimulation of different brain nuclei via ipRGCs. Apart from the 
suprachiasmatic nuclei, the intrinsically photosensitive retinal ganglion cells (ipRGCs) 
also send signals via a nonimage-forming (NIF) route to different nuclei. These include: 
medial amygdala, dorsomedial (DNH) and paraventricular nuclei of the hypothalamus, 
habenula, ventrolateral pre-optic nucleus (VPN), superior colliculus, olivary pretectal 
nucleus (OPN),  periaqueductal gray, & nucleus of the stria terminalis. Figure from 
Oldham and Ciraulo, 2014 
 
 
 
A Zeitgeber, derived from a German word that means ‘time giver’, is an external 
environmental stimulus that helps synchronize the body’s internal clock (Chan et al., 
2012). While serotonin rich raphe nuclei projections in the brain stem can provide 
sunlight-independent stimulation of the suprachiasmatic nuclei, bright light, when seen 
through the eye, continues to be one of the most important factors in stimulating the 
suprachiasmatic nuclei and its partner structures to correctly synchronize the body’s 
circadian rhythms (Dopierala and Rybakowski, 2015) (McKenna et al., 2018). Light is 
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the most important Zeitgeber (Chan et al., 2012). It has been determined that other 
external stimuli like exercise, darkness, temperature, eating, social interaction and 
sleeping do not have as significant of an effect in stimulating the suprachiasmatic nuclei 
(Dopierala and Rybakowski, 2015) (McKenna et al., 2018). Additionally, without light 
exposure, the noradrenergic neurons found in the locus coerulus begin to deteriorate 
(Dopierala and Rybakowski, 2015). 
 
Examining the Circadian Rhythm on a Cellular Level  
While research into the genes responsible for the circadian rhythm is a burgeoning 
new field and further research is required, scientists have identified some of the genes 
responsible for maintaining the body’s biological rhythms. Period (Per1, Per2, Per3) and 
Cryptochrome (Cry1, Cry2) are genes that help encode repressors for negative regulation 
(Hastings et al., 2008). The Clock gene seems to be responsible for maintaining the 
timing of a period and stabilized circadian rhythms, while Bmal1 (Mop3) assists the 
Clock gene with transcription (Hastings et al., 2008).  
Although still not entirely understood, the current model that explains how the 
suprachiasmatic nuclei work on a genetic level utilizes a negative feedback loop which 
functions via autoregulatory transcriptional and post-transcriptional signaling, with each 
loop lasting 24 hours (Hastings et al., 2008) (McKenna et al., 2018). The peripheral 
tissues that also display circadian gene expression seem to operate on this same type of 
feedback loop mechanism (Hastings et al., 2008).  
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The cycle starts when Circadian Locomotor Output Cycles Kaput (CLOCK) and 
Brain And Muscle Aryl Hydrocarbon Nuclear Translocator-Like1 (Bmal 1) heterodimer 
proteins fasten themselves to promoter DNA sequences, specifically E-box (Hastings et 
al., 2008) (McKenna et al., 2018) (Chan et al., 2012). This binding activates the genes 
Per and Cry—Per especially is activated in the retina and triggered when exposed to light 
(Hastings et al., 2008). The Per/Cry complex in the cytoplasm and then move to the 
nucleus where, after 12 hours, the proteins reach their top levels and trigger their post-
translational negative feedback loop (Hastings et al., 2008) (McKenna et al., 2018) (Chan 
et al., 2012). The genes hamper the remainder of gene activation that is dependent on E-
box and the Per and Cry gene levels fall (Hastings et al., 2008). Proteasomes degrade the 
remaining proteins throughout the night and by morning the cycle starts again (Hastings 
et al., 2008). These genes help regulate the tenacity and duration of a circadian cycle 
(Chan et al., 2012). Nuclear receptor proteins Rev-Erbα and RORA also help stabilize the 
proposed model. The Rev-Erbα and RORA proteins are produced with the same timing 
as the Per & Cry proteins, since their genes also posses E-box sequences (Hastings et al., 
2008). RORA activates BMal1 gene expression while Rev-Erbα suppresses it, causing 
BMal1 production to cycle (Hastings et al., 2008). BMal1 mRNA then is at its peak when 
Per expression is low, allowing BMal1 to be at a high concentration when there is 
reduced negative feedback (Hastings et al., 2008). Figure 2 shows a pictorial description 
of the transcriptional and post-translational negative feedback loop described above.  
Heme, an essential cofactor in cellular metabolism has been shown to fasten itself to and 
control the actions of Rev-Erbα, thereby showing a potential link between cellular 
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metabolism and the body’s circadian rhythms as well (Hastings et al., 2008). 
Mitochondrial oxidative phosphorylation itself displays a biological rhythmicity 
(McKenna et al., 2018). Rev-Erbα helps decrease levels of plasminogen activator 
inhibitor type 1 gene expression, a fibrinolysis regulator, and has also been implicated in 
a connection between better patient outcomes when cardiac surgery takes place in the 
afternoon (Chan et al., 2012)(McKenna et al., 2018).  
More research is needed to determine how the cell maintains a 24-hour periodicity 
attuned to the earth’s solar cycle. However, currently casein kinase 1 epsilon (Ck1ε) and 
F-box adaptor protein (Fbxl3) seem to play a role; when Ck1ε is mutated in mice, the cell 
period is reduced to 20 hours and there is increased degradation of Per proteins (Hastings 
et al., 2008). When Fbxl3 is mutated the cell period is lengthened to 27 hours and Cry 
protein levels are elevated for a longer period of time (Hastings et al., 2008).  
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Figure 2. The autoregulatory transcriptional/post-translational negative feedback 
loop which influences circadian rhythmicity. This is a simplified depiction of the genes 
involved in establishing the circadian rhythm on a cellular level. The numbers around the 
outside represent the time of day when each activity is occurring. Figure from Chan et 
al., 2012 
 
 
Within the suprachiasmatic nuclei and other peripheral tissues between 5-20% of 
all RNA is controlled by the body’s biological rhythms, depending on the type of tissue, 
while there may be an even higher percentage of proteins that are affected by circadian 
rhythms (Hastings et al., 2008) (McKenna et al., 2018).  The circadian dependent RNA 
can be responsible for creating genes which later help form ion channels or enzymes 
responsible for metabolic functions (Hastings et al., 2008). The circadian rhythm genes 
have also displayed an effect in helping coordinate certain body processes like the growth 
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and death of cells, as well as utilizing Cry genes to repair DNA (McKenna et al., 2018) 
(Lévi, 2006). Circadian timing influences c-myc, p53 and wee1 genes, genes that play a 
role in enhancing cell proliferation (Lévi, 2006). C-myc helps the cell cycle move form 
G1 to S, while wee1 helps the cell cycle pass from G2 to M (Lévi, 2006). Genes that 
include A, B1, D, E and mdm2, as well as the components Cdk2 and cyclins, which help 
regulate certain cell cycle checkpoints as well, have gene expressions which also posses a 
circadian rhythmicity (Lévi, 2006). Gadd45α, bcl2, bax and c-myc contribute to apoptosis 
in the cell, and these genes similarly express circadian oscillation (Lévi, 2006).  
 
The Circadian Rhythm and Response to Medical Interventions  
 
Besides simply setting a rhythm for biological processes, timing can also impact 
the body’s response to certain medicines and procedures. Seeing as how circadian 
rhythms influence cellular and liver metabolism, the excretion rates of the kidneys and 
the absorption of various substances, the mechanisms that medicines act on are also 
impacted by this rhythmicity (McKenna et al., 2018). Studies have shown the potential 
for chemotherapy drugs to have better tolerability, with fewer side effects and greater 
efficacy, depending on the time that the drugs are administered (McKenna et al., 2018) 
(Lévi, 2006). The time of administration of approximately 30 anticancer drugs influenced 
how toxic these drugs were; there was a 50% survival rate variation depending on the 
timing of a lethal dose in mice (Lévi, 2006). These differences were observed regardless 
of the route in which the drug was injected or the number of injections given (Lévi, 
2006). The timing of when the drug was best tolerated also corresponded with the 
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greatest antitumor effect (Lévi, 2006). In a study with children who had acute 
lymphoblastic leukemia, of those who were given evening administrations of 6-
mercaptopurine and methotrexate specifically, 80% had a survival and cancer free life 
five years after the study, as compared to 40% of those who received the drugs in the 
morning (Lévi, 2006).   Erythropoietin and heparin therapy are more effective when 
given at certain times of day, while gentamicin, an antibiotic which fights bacteria, is 
found to take longer to clear and have a higher concentration in the blood when given at 
10 p.m. versus 9 a.m. (Chan et al., 2012). In the case of hypertensive medications, 
besides just influencing effectiveness, the timing of administration of these medicines can 
help reduce morbidity due to cardiovascular disease (Chan et al., 2012). Other drugs, 
which also act on biological systems that experience a significant oscillation, such as 
drugs that prevent clotting, steroids and antibiotics, could potentially also experience 
similar enhanced effects if timed appropriately (McKenna et al., 2018). 
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Pathologies Related to Desynchronized Circadian Rhythms 
If the body’s circadian rhythms become disturbed, those body systems that are 
rhythm-dependent may become disordered, and pathological processes may develop. 
Circadian rhythms can become disturbed either via genetics and genetic mutations of 
certain genes responsible for maintaining the circadian rhythm, or via environmental 
factors like working night shifts, changed eating patterns and prescription medications 
(McKenna et al., 2018). Sleeping disorders, cancer, heart disease, diabetes, obesity and 
other metabolic syndromes, along with many other different health concerns have been 
associated with long-term circadian dysregulation (McKenna et al., 2018). Increased 
hypertensive risk and renal fibrosis has been linked to disruption of the renal circadian 
rhythm (Chan et al., 2012). There appears to be an association between people who are 
night workers and developing breast cancer, and chronically jet lagged mice have faster 
progressing tumors (Chan et al., 2012). In mice models with disturbed circadian rhythms, 
there is a reduction in cardiac compensation when the models have pressure overload 
cardiac hypertrophy (Chan et al., 2012). Resynchronization of the circadian rhythm back 
to normal cycles reverses this effect (Chan et al., 2012). Animal models with point-
mutated Ck1ε experience widespread fibrosis, inadequate cardiac muscle contraction, 
huge amounts of cell death, serious kidney issues and do not live as long as their healthy 
counterparts (Chan et al., 2012). 
There also seems to be a substantial link between the disturbed circadian rhythms 
in the body and mood disorder pathologies like depression and bipolar depression 
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(Dopierala and Rybakowski, 2015). In fact, research has shown that the different types of 
circadian rhythm genes that exist can affect who develops major depressive disorder and 
bipolar depression, how the illness progresses in the patient and the type of genes can 
affect the efficacy of certain treatments (Dopierala and Rybakowski, 2015) (Brown et al., 
2018). There is an association between those who develop seasonal affective disorder 
(SAD) and those who have a missense mutation in the melanopsin gene (OPN4), 
responsible for the melanopsin photopigment that triggers the pathway of taking light 
signals from the environment to the suprachiasmatic nuclei (Oldham and Ciraulo, 2014). 
Patients who experience seasonal affective disorder (SAD) or seasonal depression often 
also display mutations in the Per2, Cry2, Bmal1, Clock and Npas2 genes, while those 
suffering from bipolar depression might have mutations in the Per3, Cry2, Tim, Bmal1, 
Bmal2, Clock, Rev-Erb𝛼, Dbp, and CsnK1𝜀 genes (Brown et al., 2018). While more 
research is needed, so far the DNA methylation pattern in Bmal1 is sometimes found to 
be different in those with bipolar depression (Brown et al., 2018). Major depressive 
disorder has been associated with different forms of Per3, Cry1, Clock and Npas2 genes, 
while levels of Per1, Per2, Per3, Bmal1, Dbp, Rev-Erb𝛼, Dec1 and Dec 2 are often 
altered (Brown et al., 2018). Problems with melatonin synthesis or utilization can also 
become a contributing factor in developing major depressive disorder. Polymorphisms in 
aralkylamine N-acetyltransferase (Aanat) are linked to major depressive disorder, while 
polymorphisms in N-acetylserotonin O-methyltransferase (Asmt) are linked to recurrent 
depression (Brown et al., 2018). Both these genes assist with melatonin synthesis (Brown 
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et al., 2018). Table 1 goes into greater detail regarding various body systems that are 
affected when there are abnormalities in the genes that control circadian regulation.  
High concentrations of interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-𝛼), which display synchronization with the body’s biological rhythms, have a strong 
association with major depressive disorder and bipolar disorder (Brown et al., 2018) 
(Chan et al., 2012). These and other cytokines are often elevated in patients with major 
depressive disorder, with levels peaking and staying raised during particularly difficult 
depressive episodes, suggesting that patients with long-term depression also 
simultaneously experience a chronic inflammatory response (Brown et al., 2018).  In 
patients with bipolar depression, cytokine levels are also often elevated, and while levels 
can fluctuate between the manic and depressive states, there is still a chronic 
inflammatory response present, with different types of cytokines peaking during 
depressive and manic episodes (Brown et al., 2018).  
In patients with Alzheimer’s dementia, there are irregular sleeping patterns but 
normal cortisol levels, suggesting that the suprachiasmatic nuclei are still trying to 
establish rhythmicity but are not able to send the appropriate messages to the brain 
centers responsible for controlling sleep or wake states (Hastings et al., 2008). In patients 
with Huntington’s disease there are also irregular sleeping patterns and in mice, disrupted 
circadian rhythm gene expression within the suprachiasmatic nuclei. Interestingly, when 
mice with Huntington’s disease are forced into a normal sleep pattern through use of 
prescription medication, there is enhanced gene expression and a reduction in cognitive 
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decline (Hastings et al., 2008). In the intensive care unit (ICU), delirium is sometimes 
experienced after a critical injury (McKenna et al., 2018). ICU delirium, a syndrome 
potentially caused by desynchronized circadian rhythms and interrupted sleep while in 
the ICU, can impact 80% of critically ill patients and has been linked to increased risk of 
death or long-term illness  (McKenna et al., 2018) 
 Ironically, just getting more sleep is not helpful for restoring balance to the 
circadian rhythms. In fact, patients taking sedatives, or benzodiazepines especially 
(which cause a phase-shift in the patient’s sleeping schedule), experience disorganized 
sleep patterns, increased chances of experiencing ICU delirium, and minimized melatonin 
secretion (McKenna et al., 2018). The quality of sleep that the patient obtains is also 
important. Poor sleep quality can contribute to how severely a depressive episode will 
manifest itself as (Berg et al., 2018). As mentioned earlier, what is most important is the 
timing of when the patient goes to sleep, the quality of sleep and having enough and 
bright exposure to light; because as stated before, light is one of the greatest stimulators 
of the suprachiasmatic nuclei, while sleep alone has a much weaker effect.  
 
Table 1. Pathologies as a result of Abnormal Circadian Gene Presentation 
Body System  Genes Involved Normal Function Effects of 
Disturbance 
Immune System -both central and 
peripheral: PER1, 
PER2, BMAL1, 
CLOCK 
 -Gene disturbances in 
natural killer cells: ↓ 
cytolytic factors (ex: 
granzyme B, perforin), ↑ interferon-𝛾 
 
 -PER2   - point 
mutation/deficiency 
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àno circadian rhythm 
present in interferon-𝛾 
at gene and protein 
levels  
-↓ interferon-𝛾, 
interleukin-1𝛽 
Cardiovascular 
system 
-Clock, Ck1ε   -Lack/mutation of 
Clock geneàloss of 
circadian pattern 
platelet aggregation, 
and heart rate, ↓ 
bradycardia, 
triglycerides (net and 
synthesis levels), 
lipolysis, ↑ oxygen 
and fatty acid 
oxidation use in 
myocardial cells  
-Point mutation in 
Ck1εà myocardial 
cells unable to contract 
properly 
 
 -Rev-Erb𝛼 -↓ plasminogen 
activator inhibitor 
type 1 gene 
expression 
 
 PER2, BMAL  change in PER2, 
BMAL expressionà ↓ 
cardiac compensation 
in hypertrophic 
conditions 
Hepatic system Cry1, Cry2 - ↑ Cry1à ↓ blood 
glucose levels, ↑ 
insulin sensitivity 
 
Renal System Ck1ε  Point mutation in 
Ck1εà severe renal 
dysfunction 
Autonomic 
Nervous System 
PER3  Different forms of 
PER3àchanged 
sympathovagal 
balance  
Cell Growth Cry DNA repair  
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 Ck1ε  Point mutation in Ck1ε 
à apoptosis 
Psychological   OPN4 Formation of 
melanopsin 
photopigment  
Missense 
mutationàSeasonal 
Affective Disorder 
 Per2, Cry2, Bmal1, 
Clock, Npas2 
 MutationsàSeasonal 
Affective Disorder 
 Per3, Cry2, Bmal2, 
Clock, Dbp, Tim, 
Rev-Erb𝛼, CsnK1𝜀   MutationsàBipolar Depression 
 Bmal1  Different methylation 
patternàBipolar 
Depression 
 Per3, Cry1, Clock, 
Npas2 
 VariationsàMajor 
Depressive Disorder 
 Per1, Per2, Per3, 
Bmal1, Dbp, Rev-
Erb𝛼, Dec1, Dec 2  Altered concentrationsàMajor Depressive Disorder 
 Aanat, Asmt Melatonin 
synthesis/use  
Variation in Aanatà 
Major Depressive 
Disorder 
 
Variation in Asmtà 
recurrent depression 
 
Information from Brown et al., 2018, Chan et al., 2012, Lévi, 2006, McKenna et al., 2018 
and Oldham and Ciraulo, 2014. 
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CHRONOTHERAPY  
Mood Disorders 	
 Mood disorders will affect an estimated one in seven people (Brown et al., 2018). 
The World Health Organization cites depression as being the number one cause of illness 
and disability worldwide, with more than 300 million people now suffering from the 
condition (World Health Organization, 2018). The number of people affected also 
continues to rise, with an 18% increase in prevalence between 2005 and 2015 (World 
Health Organization, 2018).  As of 2016, in the United States the lifetime prevalence is 
estimated to be 21%, and globally the lifetime prevalence is conservatively estimated to 
be about 15% (Penders et al., 2016). The prevalence of bipolar depression is about one 
percent (Henriksen et al., 2016).  
Bipolar disorders are defined as a group of mood disorders in which a person 
experiences both major depressive episodes and episodes of manic or hypomanic 
behavior, with normal moods interspersed (World Health Organization, 2018) (Brown et 
al., 2018). Manic episodes are defined by experiencing surly or sensitive mood, 
magnified sense of self, high bouts of energy possibly leading to hyperactivity, a greater 
likelihood of engaging in risky behavior, problems sleeping or a lack of sleep, and 
changes in mental state--sometimes leading to psychosis (Henriksen et al., 2016)(World 
Health Organization, 2018). Manic episodes, which can last for weeks, oftentimes lead to 
the patient being injured or killed in an accident, or there are social consequences, like 
issues at work (Henriksen et al., 2016).  Having a psychotic manic episode also raises the 
chances of having a depressive episode in the future (Henriksen et al., 2016). Someone 
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suffering from bipolar depression will usually spend most of his or her time in a 
depressive state (Benedetti et al., 2013).  
Major depressive disorder is partially defined as someone experiencing more than 
one major depressive episode and the absence of manic or hypomanic episodes (Brown et 
al., 2018). Depression can be classified as mild, moderate, or severe, depending on the 
type and number of symptoms present (World Health Organization, 2018). When 
depression lasts a long time, it can then be classified as chronic, while depressive 
episodes that keep re-occurring are classified as recurrent (World Health Organization, 
2018). Some symptoms of depression include low self esteem, reduced energy leading to 
a decreased activity level, anxiety, feelings of guilt, interrupted sleep patterns and loss of 
appetite (World Health Organization, 2018). Additionally, cognitive disturbance is a 
large umbrella that covers many of the symptoms of major depressive disorder, 
including: impaired cognition, trouble with decision making, loss of pleasure in every day 
activities or activities that used to bring joy, an increase in suicidal thought patterns, 
slowing of psychomotor skills and general negative feelings (Brown et al., 2018). 
Executive function, memory, attention, and concentration are all affected, with 50% of 
people who experienced one or more major depressive episodes suffering cognitive 
disturbances that were of clinical significance (Brown et al., 2018). These cognitive 
symptoms can occur every once in a while or be persistent and chronic in those suffering 
with major depressive disorders (Brown et al., 2018). Chronic severe depression can lead 
to deterioration of brain matter and neurodegeneration (Brown et al., 2018). In fact, 
patients who experienced multiple instances of major depressive episodes have decreased 
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brain volume and glial cells in multiple regions of the brain, including the hippocampus, 
caudate nucleus, anterior cingulate cortex and prefrontal cortex (Brown et al., 2018). 
Magnetic resonance spectroscopy has found metabolites linked to neuronal death and 
increased circulating inflammatory markers in those with this disease (Brown et al., 
2018). There appears to be a connection lacking between the prefrontal and limbic areas, 
as well as reduced integration between various areas of the brain, including: the right 
caudate, a portion of the corpus callosum, the brain stem, projections from the posterior 
thalamus, the corona radiate and a portion of the longitudinal fasciculus (Brown et al., 
2018).  Post mortem findings have displayed shrunken neuronal cells and decreased 
amounts of neurons, synapses and glial cells; however, it is still unknown whether those 
findings are linked to having major depressive disorders or are a precursor for the disease 
(Brown et al., 2018). The nuerodegeneration found in major depressive disorder and 
bipolar depression has similar markers as those related to the aging process--involving 
similar inflammatory cytokines, shortened telomeres and decreased levels of plasma 
antioxidants (Brown et al., 2018).    
 
Chronotherapeutics as a Treatment for Mood Disorders         
Circadian rhythm desynchronization along with maladaptive immune reactions 
and increased oxidation contributes to the neurodegeneration found in severe depression 
(Brown et al., 2018).  Those with major depressive disorder often have heightened 
concentrations of the molecules 8-hydroxy-2’-deoxyguanosine (8-OHdG) and 
malondialdehyde (MDA) which increase oxidation and oxidative stress in the body. They 
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also tend to have lower levels of glutathione (GSH), glutathione peroxidase (GPx) and 
superoxide dismutase (SOD) and which have properties that work against oxidative stress 
(Brown et al., 2018).  It is still undetermined as to whether depression is caused or 
enhanced by a circadian imbalance or if depression itself causes and exacerbates 
circadian rhythm desynchronization (Brown et al., 2018). Regardless, depression and 
other mood disorders are deleterious to health.  
Conventional treatment options have often relied on the use of antidepressant 
medication. However the World Health Organization has advised clinicians to examine 
other treatment modalities, either in lieu of, or in conjunction with current 
pharmacological therapies (World Health Organization, 2018) The World Health 
Organization advises clinicians to be aware of the negative effects that occur when 
patients take antidepressant medication. They advise that while medication can be useful 
for those who have moderate to severe depression, it should not be the first approach used 
in tackling mild depression or depression in adolescents. They also warn providers to not 
use antidepressants in children at all, and caution clinicians to carefully monitor the 
administration and use of antidepressants in adolescents (World Health Organization, 
2018). Additionally, a large epidemiological study found that antidepressant use did not 
succeed in reducing suicide attempts over a lifetime (Benedetti et al., 2013). The United 
States Food and Drug Administration (FDA) has found that for those under 25 years old, 
antidepressants can increase suicidal thoughts, their effect is neutral for those between 25 
and 64, and for those over the age of 65 antidepressants can be helpful in preventing 
suicide (Benedetti et al., 2013). Clinicians can and have been recommending 
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psychological approaches to treatment, such as behavior therapy (both activation and 
cognitive) and interpersonal psychotherapy but these interventions have many barriers 
such as a lack of access to properly trained professionals (World Health Organization, 
2018). In 2014, there were 60 countries that had less than 1 psychiatrist per 100,000 
people (World Health Organization, 2018).  However, the use of chronotherapeutics has 
emerged as a new approach for tackling certain mood disorders.  
 
Chronotherapy versus Mood Disorders: Results  
 
Chronotherapy, or treatments that seek to use external, environmental stimuli 
which affect the body’s natural homeostasis, in a consistent and regimented way, can 
help stabilize disordered circadian rhythms and bring them back to a normal balance 
(Dopierala and Rybakowski, 2015). There are many treatment modalities that fall under 
the umbrella term of chronotherapy. These include: sleep deprivation (both partial and 
total), sleep phase advance, pharmacotherapy, and phototherapy or light therapy 
(Dopierala and Rybakowski, 2015). Light therapy can include bright light therapy, dark 
therapy or dawn and dusk simulation therapy (Dopierala and Rybakowski, 2015). All of 
these treatments can be used either individually or in conjunction with one another.  
Sleep Deprivation/Wake Therapy 
 One of the common uses of chronotherapy is sleep deprivation, either total or 
partial, for the treatment of depression or depressive disorders. Total sleep deprivation is 
also sometimes named wake therapy.  In total sleep deprivation, the patient is most often 
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kept completely awake for 36 hours (Dopierala and Rybakowski, 2015). In a meta-
analysis of 1700 depressed patients, 50-60% experienced a short-lived improvement in 
depressive symptoms after total sleep deprivation (Dopierala and Rybakowski, 2015). 
While the exact length of time the patient needs to be kept awake to incur the full benefits 
of sleep deprivation therapy is not known, a small clinical effect was shown after being 
awake for two hours in the middle of the night, and more specifically when longer 
periods of sleep deprivation occur in the second half of the night (Dopierala and 
Rybakowski, 2015). However, the anti-depressant effects of sleep deprivation are often 
short-lived, and after the patient returns to a normal sleep schedule, the patient’s 
symptoms often return to their baseline intensity pre-therapy (Dopierala and Rybakowski, 
2015). To enhance the antidepressant effect of chronotherapy clinicians can combine 
multiple treatment options. After sleep deprivation is combined with pharmacological 
approaches, it is reported that the medications work faster and are more effective than 
when pharmacological interventions alone are used (Dopierala and Rybakowski, 2015). 
Combining the two therapies also causes the depressive symptoms to abate for a longer 
time than sleep deprivation alone, with a positive response sometimes lasting for months 
after the initial sleep deprivation sessions (Dopierala and Rybakowski, 2015) (Brown et 
al., 2018). Combining sleep deprivation with bright light therapy can also prolong the 
amelioration of depressive symptoms (Dopierala and Rybakowski, 2015). Besides just 
being used for depressive disorders, sleep deprivation has been minimally associated with 
a reduction in negative schizophrenic symptoms (Dopierala and Rybakowski, 2015). 
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Mechanistically, sleep deprivation is thought to reset the genes in the brain responsible 
for the regulation of the body’s circadian rhythm (Brown et al., 2018). 
 
Sleep Phase Advance 
 Another modality of chronotherapy is sleep phase advance, which refers to 
moving the body’s sleep-wake pattern forward by combining sleep deprivation and bright 
light therapy (Dopierala and Rybakowski, 2015). Being exposed to light in the early 
morning subsequently leads to persons experiencing the sleep phase earlier, categorized 
as a phase advance (Oldham and Ciraulo, 2014). A phase delay occurs when persons are 
exposed to bright light in the evening, consequently delaying the time until the sleep 
phase occurs (Oldham and Ciraulo, 2014). Most patients with major depressive disorder 
experience sleep delay (Oldham and Ciraulo, 2014). A forward shift of the sleep-wake 
cycle appears to be associated with an improvement in bipolar depression symptoms, 
while some research shows that the larger the correction of the sleep phase advance the 
greater the improvement in depressive symptoms (Oldham and Ciraulo, 2014) (Dopierala 
and Rybakowski, 2015). 
 
Bright Light Therapy 
 
 Bright light therapy has become especially famous and utilized as a treatment for 
seasonal affective disorder (Brown et al., 2018). It is now one of the front-line utilized 
therapies for this disorder and it shows effectiveness as a treatment for bipolar depression 
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and major depressive disorder as well (Oldham and Ciraulo, 2014) (Brown et al., 2018). 
In seasonal affective disorder, bright light therapy has an effect size of .84 and in major 
depressive disorder it has an effect size of .53; these effect sizes are comparable to 
existing treatments, specifically antidepressants and a variety of prescription medications, 
including other general psychiatric medications (Oldham and Ciraulo, 2014). In seasonal 
affective disorder, the effect size for bright light therapy is greater than the effect size of 
current prescription medication options (Oldham and Ciraulo, 2014, 2014).  Bright light 
therapy, implemented in the mornings and after the initial critical illness phase when 
patients are under many sleeping pills, has been shown to decrease ICU delirium and 
disturbed sleep (McKenna et al., 2018). It also shows potential as a treatment option for 
treating depression during pregnancy and perinatal depression, as opposed to medications 
during this particularly sensitive time (Brown et al., 2018). For neonates in the hospital, 
when exposed to a consistent light and darkness schedule, the babies were able to gain 
weight faster and leave the hospital earlier; so providing appropriate rhythmicity and light 
training early in life may be helpful in hospital settings to help improve neonatal 
outcomes (McKenna et al., 2018). Bright light therapy is often administered after the 
body’s core temperature reaches its lowest point, generally two or three hours before the 
patient is about to wake up-- this allows the body’s circadian rhythms to reset themselves 
(Bartlett et al., 2013). Those administering this therapy must make sure the light is at the 
appropriate intensity (between 2,500-10,000 lux around the blue-green end of the light 
spectrum is considered an effective therapeutic dose) and that the subjects are close 
enough to the light source and exposed to it for a long enough period of time (Bartlett et 
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al., 2013). While other traditional treatments for major depressive disorder often take up 
to two weeks to start showing minimal effects, and up to a month or more before major 
symptoms are addressed, a review sponsored by the American Psychiatric Association 
found that bright light therapy demonstrates statistically significant improvements in the 
treatment of mood disorders after one week (Oldham and Ciraulo, 2014). In those with 
seasonal affective disorder, bright light therapy increases the circadian rhythm amplitude 
associated with core body temperature, suggesting that there is an effect on regulating 
body temperature and that subsequently bright light therapy is acting on the sympathetic 
nervous system (Oldham and Ciraulo, 2014). Patients who have the PER3 5/5 allele show 
a greater response to blue enriched bright light than those with the PER3 4/4 variant, 
illuminating that genes, yet again, play a role in the efficacy of some chronotherapeutic 
treatments (Oldham and Ciraulo, 2014). Besides its usefulness as a therapy option, bright 
light therapy is also quite safe. There are almost no systemic deleterious side effects such 
as weight gain or sexual dysfunction like is the case with antidepressant prescription 
medications, there is no real way to overdose on the treatment, there is no teratogenicity, 
and there are no documented cases of discontinuation syndrome or particularly 
deleterious side effects to stopping treatment (Oldham and Ciraulo, 2014). There is also 
no digestive absorption component so the treatment is not restricted by either absorptive 
or clearance limitations (Oldham and Ciraulo, 2014). Additionally, it can be administered 
at home, eliminating the patients need to go to an office for treatment or therapy, and 
defeating a usual barrier of access. 
	 	
 28 
Bright Light Therapy and Pregnancy 
As a result of its relative safety compared to other current and conventional 
therapies, bright light therapy has found a niche in being potentially utilized for the 
treatment of major depressive disorder in pregnant women and in women suffering from 
postpartum depression. Depression during pregnancy is more common than people think, 
with one in 10 women experiencing depression while pregnant (Wirz-Justice et al., 
2011). Additionally, having depression while pregnant is one of the most important 
factors in determining whether a pregnant woman will acquire post-partum depression 
(Wirz-Justice et al., 2011). Having depression during pregnancy exposes both the fetus 
and the pregnant mother to a variety of risks. Being pregnant and depressed can lead to 
more complications, preterm delivery, low birth weight, and an increased chance of 
having a newborn that ends up in neonatal intensive care (Wirz-Justice et al., 2011). 
When the babies of depressed pregnant mothers become infants they tend to have a 
higher chance of developing cognitive problems and having difficulty regulating 
emotions or behavior  (Wirz-Justice et al., 2011). For the mothers, besides the increased 
predilection of having post-partum depression, depression increases the likelihood that 
they fail to seek appropriate nutrition and prenatal care, they then fail to gain an 
appropriate amount of weight, have an increased likelihood of using nicotine products, 
alcohol or other drugs, and can have trouble establishing the appropriate mother-child 
bonds (Wirz-Justice et al., 2011). The mothers are also more likely to need surgical 
interventions during delivery (Wirz-Justice et al., 2011). Treating depression during 
pregnancy is therefore an important health issue to address. However, all currently 
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available antidepressants are able to pass through the placenta and there could be 
numerous unknown effects on the fetus, both while in utero, after delivery and beyond 
(Wirz-Justice et al., 2011). So far, clinicians are wary about utilizing antidepressant 
medications during pregnancy as they can stunt the growth of the fetus, increase the 
chances of the baby being delivered earlier than expected, cause pulmonary hypertension 
or even cause the baby to experience withdrawal once born, among other effects that are 
hitherto unknown (Wirz-Justice et al., 2011).  Health care providers, therefore, need an 
alternative that is both safe and effective, and bright light therapy could be that option. In 
a five week randomized control trial of pregnant women with depression who were 
exposed to 7000 lux light after awakening for 60 minutes every day, 60% of the women 
experienced a reduction in depressive symptoms (Wirz-Justice et al., 2011). In a further 
randomized, double blind, placebo-controlled study of pregnant women with depression, 
lasting for the same five weeks and 7,000 lux, the researchers found a statistically 
significant decrease in depressive symptoms (Wirz-Justice et al., 2011). The results of 
that study are seen in Figure 3. Here too, patients who were more severely depressed had 
a greater improvement after the bright light therapy (Wirz-Justice et al., 2011). 
Additionally, the subjects went down four points in the Hamilton Depression Rating 
Scale, whereas most antidepressant medications achieve a decrease of two points on the 
same scale (Wirz-Justice et al., 2011). Bright light therapy is also an attractive option for 
soon to be mothers with depression since the possibility of at home treatment means they 
don't have to worry about finding childcare or transportation, increasing chances of 
treatment compliance (Wirz-Justice et al., 2011). Bright light therapy can then be an 
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effective treatment option for pregnant women suffering from mood disorders and those 
with post-partum depression. 
 
 
Figure 3. Results of a 5 week randomized, double blind, placebo-controlled trial on 
the effect of bright light therapy (7000 lux) on pregnant women with depression. 
Participants were exposed to 60 minutes of light every day. Response meant an 
improvement ≥50% while remission was categorized as ≥50% and a final HDRS and 
Atypical Depression Supplement (SIGH-ADS) score of ≤8. Participants experienced a 
statistically significant improvement in their depression symptoms. HDRS-17 stands for 
17-item Hamilton Depression Rating Scale. Figure from Wirz-Justice et al., 2011 
 
 
 
 
Blue Light Blocking Glasses 
 A simple chronotherapeutic option is the use of blue blocking glasses over the 
eyes in the nighttime (Brown et al., 2018). As mentioned before, the retinal ganglion cells 
are most strongly stimulated by light in the blue part of the UV spectrum. When these 
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cells are stimulated they send signals to the suprachiasmatic nuclei, which then stop 
melatonin production. In today’s society, individuals are constantly bombarded with blue 
light, for example via electricity and technological advances like computer and phone 
screens. When these items are used in the evenings they can delay the secretion of 
melatonin and this can cause disturbances in sleep patterns and subsequently circadian 
rhythms. Exposure to five hours of a LED (Light Emitting Diode) screen, like those that 
are present in televisions, in the evening can stop melatonin secretion (van der Lely et al., 
2015).  Blue light cannot be artificially administered in the morning to help stimulate a 
sleep phase advance, like bright light therapy does, because large amounts of blue light 
exposure have been linked to reductions in photoreceptor sensitivity (Brown et al., 2018).  
Therefore, blue blocking glasses have been developed, which, like the name suggests, 
block blue light from reaching the sensitive photoreceptors. The glasses allow for the 
normal secretion of melatonin in the evening and have been proven effective in restoring 
evening melatonin secretion in various populations, such as in night shift workers and 
children exposed to blue light emitting devices, all with no side effects (Brown et al., 
2018) (van der Lely et al., 2015). In night shift workers who wore blue blocking glasses 
in the daytime, they experienced more sleep when they rested during the day and their 
daytime sleep was less fragmented (Sasseville et al., 2009). Adolescents who used blue 
blocking light glasses had significantly higher levels of melatonin before sleep, as 
measured in salivary samples, than those in the control group (van der Lely et al., 2015). 
In a study of normal individuals whose only complaint was poor quality sleep, utilization 
	 	
 32 
of these glasses three hours before bedtime found a statistically significant improvement 
in sleep quality and mood after three weeks (Burkhart and Phelps, 2009). 
 
Blue Blocking Glasses and Manic Episodes in Bipolar Depression 
 
These types of glasses have also been helpful additional tools in treating manic 
episodes in bipolar depression, with ameliorative effects being observed after three days 
(Brown et al., 2018). The treatment’s ability to work quickly is especially important since 
manic episodes can last for weeks (Henriksen et al., 2016). Most current treatments that 
utilize the typical anti-manic and bipolar medications take a longer time to start working 
(Henriksen et al., 2016). Newer research has pointed to an association between a change 
in light conditions and the onset of a new bipolar manic episode; thus, blocking some of 
these light changes could alleviate or delay a new manic episode (Henriksen et al., 2016). 
Figure 4 shows the percent of blue light that is transmitted when wearing blue blocking 
glasses versus clear lenses. In one randomized, placebo controlled study, the authors 
found that wearing blue blocking glasses from 6 p.m. to 8 a.m. for one week in the 
hospital when having a manic bipolar episode was highly effective in reducing manic 
symptoms (Henriksen et al., 2016). There was a significant decrease in the Young Mania 
Rating Scale (YMRS) in those wearing the blue blocking glasses three days after starting 
the treatment, with effect sizes for the glasses intervention hovering between 1.05 to 1.86, 
which are very high effect values (Henriksen et al., 2016). Some symptoms from the 
Young Mania Rating Scale were diminished after only one night of use, with side effects 
being headache and lower energy levels (Henriksen et al., 2016). This illuminates that 
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this treatment is effective and starts working much more quickly than traditional 
treatments. The low side effect profile is another positive aspect of the treatment, 
especially when compared to the side effect profile of the conventional prescription drug 
treatments used to treat manic episodes. It was easy for the patients to use the glasses, 
even in a manic state, lowering one barrier to accessibility (Henriksen et al., 2016). 
Finally, some of the symptoms in bipolar depression exhibit a close relationship to having 
irregular circadian rhythms (Henriksen et al., 2016). As elucidated before, blue blocking 
glasses can be helpful in promoting melatonin secretion and subsequently assist in the 
realignment of circadian rhythms. In a study that had bipolar depressives wearing blue 
blocking glasses in the evening, 50% had improved sleep (Henriksen et al., 2016). This 
could be another potential use for blue blocking glasses in treating bipolar depression.  
 
Figure 4. Percent transmittance of light versus wavelength when blue blocking 
glasses (BB) are worn versus clear glasses (placebo). Figure taken from Henriksen et 
al., 2016. 
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Melatonin 
 The use of melatonin supplements to regulate the circadian rhythm also falls 
under the umbrella of chronotherapeutics. Melatonin is considered to be a chronobiotic, 
or a chemical that is able to resynchronize short or long-term irregularities of the 
circadian rhythm (Bartlett et al., 2013). A chronobiotic can also be a chemical that is able 
to act in a preventative manner to avoid circadian rhythm changes after an external 
environmental factor compromises the stability of the circadian rhythm (Bartlett et al., 
2013). Besides being a sleep aid and advancing the sleep-wake cycle, melatonin release is 
also responsible for helping decrease the core body temperature during sleep and 
subsequently raising the body temperature in the peripheries (Bartlett et al., 2013). 
Melatonin can be a useful treatment for those who are resistant to light based treatments, 
such as patients who are blind and those who might experience deterioration or aging of 
the eyes, like the elderly (Brown et al., 2018). The elderly often experience a decreased 
sensitivity to the blue light that stimulates the melanopsin containing ganglion cells that 
subsequently stimulate the suprachiasmatic nuclei, due to excessive constriction of the 
pupil or a reduced ability of light to pass through the lens of the eye (Brown et al., 2018). 
The blind lack the photoreception of bright light in general, and some blind people have 
been shown to experience imbalances in the body’s biological rhythms, such as delayed 
sleep phase insomnia (Brown et al., 2018). In blind patients, a small dose of 0.5 mg 
melatonin is shown to be useful in restoring circadian imbalance and enhancing sleep 
quality, and even 0.025 mg can resynchronize some blind patients (Brown et al., 2018). 
Dosages as small as 0.3 to 0.5 mg have also been shown to be just as effective as 3.0 mg 
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for helping patients fall asleep (Bartlett et al., 2013). Melatonin can therefore be useful 
for the niche populations of the blind or elderly in a way that is unique compared to other 
treatments. Those who suffer from small lesions or early deterioration of the 
suprachiasmatic nuclei and its related pathways can also benefit from melatonin use 
(Brown et al., 2018). Depending on the condition it is being used to treat, the timing of 
when melatonin is administered is the most important variable to its success as a therapy, 
followed by dosage as the next secondary factor (Bartlett et al., 2013). Timing is 
important because the length of the phase angle delay, or the time between when 
melatonin secretion begins and sleep begins, is significantly correlated with depression-- 
in healthy patients the phase angle delay is two hours (Oldham and Ciraulo, 2014). 
Properly timing the administration of melatonin is a tool in the battle of trying to reset the 
phase angle delay and subsequent circadian rhythm to normal parameters, and decreasing 
the risk of developing depression.  
Combination Chronotherapy 
  The most effective treatment of circadian based mood disorders seems to be a 
comprehensive attack, using almost all the tools in the chronotherapy arsenal. In a study 
where total sleep deprivation, sleep phase advance, bright light therapy and anti-
depressant drugs were used concurrently, there was a greater decrease in depressive 
symptoms than if prescription dugs were used, and the symptoms stayed away for longer 
than if chronotherapeutics were the sole treatment option (Dopierala and Rybakowski, 
2015). In other studies which utilized bright light therapy, wake therapy and sleep phase 
advance, there was relief from symptoms within days, as compared to weeks or months 
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with traditional approaches (Oldham and Ciraulo, 2014). Combination sleep deprivation 
and bright light therapy resulted in improved clinical and personal measurements of 
depression symptoms along with a reduced ratio of glutamate and glutamine divided by 
creatine, in those with non-psychotic bipolar depression (Oldham and Ciraulo, 2014). In 
patients suffering from Alzheimer’s, those who combined melatonin and bright light 
therapy have found some relief from symptoms, with the treatment helping patients 
sustain a more restful nighttime sleep and subsequently reducing daytime drowsiness 
(Dowling et al., 2008) (Brown et al., 2018). Those suffering from major depressive 
disorder and bipolar depression also found relief from depressive symptoms when 
pharmacological interventions were combined with at least 30 minutes of 5000 lux bright 
light therapy (Penders et al., 2016). Unlike other treatments, a combination of sleep 
deprivation, bright light therapy and lithium use for one week was able to quickly reduce 
depressive symptoms and suicidal thoughts in 70% of those with antidepressant drug-
resistant bipolar depression, with 55% maintaining the benefit two weeks after treatment 
(Benedetti et al., 2013). Other treatments thus far have not been as fast acting in reducing 
suicidal thoughts (Benedetti et al., 2013). Additionally, combination lithium, repeated 
total sleep deprivation and bright light therapy helped those with bipolar depression 
achieve remission of symptoms in over 50% of subjects (Benedetti et al., 2013). 
 Chronotherapy is also a useful option for patients who are resistant to traditional 
prescription drug options. Although the remission rate is lower than for those who are 
non-resistant, when sleep deprivation has been combined with sleep phase advance and 
bright light therapy, there has been a decrease in depressive symptoms and it is still a 
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useful option for those whom treatment has failed (Dopierala and Rybakowski, 2015). Of 
those who combined the chronotherapies listed with prescription medications, 62% went 
from treatment resistance to finding improvement (Dopierala and Rybakowski, 2015). In 
one study which utilized wake therapy, bright light therapy, maintaining a constant sleep 
time, along with traditional medication in previously treatment resistant patients, 
researchers found that by day six, treatment was effective for 41% of the patients and 
19% went into remission (Kragh et al., 2018). Finally, as mentioned previously, in a 
study of those who were anti-depressant resistant and suffering from bipolar depression 
and suicidal thoughts, when treated with lithium, bright light therapy and limited and 
controlled total sleep deprivation, suicidal thoughts declined in all 141 patients who 
completed the study, while 55% found an improvement in depressive symptoms, even 
one month after the study was complete (Dopierala and Rybakowski, 2015) (Benedetti et 
al., 2013). A multifaceted approach to using chronotherapy can have some impactful 
effects in reducing the duration and severity of mood disorder symptoms.   
 Although mood symptoms can be alleviated, often times the cognitive deficits that 
are acquired as depression progresses cannot be fixed, and these require their own 
therapeutic interventions (Brown et al., 2018). Research utilizing anti-inflammatory 
treatments seems to leading the forefront of tackling this issue, which can be helpful for a 
subset of patients whose mood disorders have an immune system connection (Brown et 
al., 2018).  
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Chronotype and its Influence on Mood Disorders and Chronotherapy 
 The ‘chronotype’ of different patients seems to have an effect on both their 
likelihood of acquiring certain mood disorders, as well as their responsiveness to 
different chronotherapeutic treatments (McKenna et al., 2018). A chronotype is defined 
as the point during the day when a person may experience their peak mental and physical 
performance  (McKenna et al., 2018). While persons can fall along a spectrum, the two 
ends include “morningness” and “eveningness” (McKenna et al., 2018). As the names 
suggest, those with a morningness chronotype have a tendency to wake up early in the 
morning, experience their peak levels of physical and mental energy similarly early in the 
day and go to sleep early in the evening, and vice-versa for eveningness (McKenna et al., 
2018). EEG studies of slow wave brain activity have shown that those who identify with 
the eveningness chronotype tend to have a distinct pattern that is different from those 
who have the morningness chronotype during rapid eye movement (REM) and non-REM 
sleep (Berg et al., 2018). The chronotype someone exhibits is largely influenced by 
genetics, age and sex (Berg et al., 2018) (McKenna et al., 2018). The job someone has, as 
well as the lifestyle they lead can also exert an influence on chronotype expression, and 
reduced morning light and increased exposure to artificial and blue light in the evenings 
has been associated with an eveningness preference (Berg et al., 2018) (van der Lely et 
al., 2015). Identifying with the eveningness chronotype seems be a predicting factor in 
whether or not someone will be impacted by mood disorders (Berg et al., 2018). There 
are strong associations between displaying the eveningness chronotype and depression. 
Patients with this chronotype have a higher incidence of depressive symptoms with 
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greater intensity, are more likely to be diagnosed with major depressive disorder, and 
tend to have been treated for depression in the past or are currently seeking treatment 
(Berg et al., 2018). Those with major depressive disorder who were more eveningness 
chronotype also had greater tendency towards suicidal ideation than those with a 
morningness preference (Berg et al., 2018). The eveningness chronotype when exhibited 
in adolescents also has similar predictive effects, with the evening preference showing a 
link to an increase in symptoms or reoccurrence of depression over the span of one year 
(Berg et al., 2018). This chronotype also has a tendency to experience fragmented and 
disturbed sleep, with worse quality, further exacerbating the severity of depression 
symptoms (Berg et al., 2018). Preliminary studies seem to suggest that those who 
experience depression with positive diurnal variation or, eveningness and experiencing 
better moods in the evenings, have a tendency to respond better to chronotherapeutic 
interventions, both in the short and long term (Kragh et al., 2018). Since there is an 
association with the patient’s chronotype and responsiveness to treatment, those 
considering using chronotherapy as a treatment option should administer questionnaires 
like the Munich Chronotype Questionnaire and the Horne-Ostberg Morningness-
Eveningness Score—questionnaires which help establish the dim-light melatonin onset 
time, the closest measure to finding someone’s chronotype (McKenna et al., 2018). This 
will allow health care providers to estimate the efficacy of a certain chronotherapeutic 
treatment for a patient. In adults, the ability to return to normal sleep patterns has also 
been linked to how and if a chronotherapeutic treatment will work (Oldham and Ciraulo, 
2014). 
	 	
 40 
Chronotherapy in Juvenile Depression 
 
 Finally, chronotherapy can be a useful tool in helping another vulnerable 
population and assist with treating juvenile depression. In 2014, there was a prevalence of 
five to six percent of adolescents developing juvenile depression with a rate that has been 
increasing four to eight percent a year; this makes it one of the most common adolescent 
psychiatric issues and a great public health concern (Gest et al., 2014). Girls are twice as 
affected as boys, and those who develop juvenile depression are at a 50-60% greater risk 
of developing long-term chronic recurrent depression leading into adulthood (Gest et al., 
2016) (Gest et al., 2014). Adolescents tend to have decreased sleep times for a variety of 
reasons: from electronic use, a preference for sleeping later, early school start times etc.--
however shorter sleep times and falling asleep later have also been associated with an 
increase in depression and suicidal thoughts (Gest et al., 2014). Of those with juvenile 
depression, 75% also concurrently suffer from insomnia (Gest et al., 2014). Treating 
adolescents with conventional therapies is difficult. They do not respond as readily to 
conventional medications and cognitive behavioral therapy as their adult counterparts, 
with a response rate of 37% under the most rigorous and comprehensive therapy 
conditions (Gest et al., 2014). Of those who respond to treatment, 50% still experience 
some symptoms and after five years 42.9% have experienced another depressive episode 
(Gest et al., 2014). Additionally, clinicians need to be extremely cautious if they decide to 
prescribe antidepressant medications to adolescents. With some prescription medications, 
adolescents have a higher risk than adults of harming themselves, having suicidal 
ideation or attempting to commit suicide (Gest et al., 2014). Since 2003, the United 
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Kingdom has banned most selective serotonin reuptake inhibitors (SSRIs) and other 
drugs for those under 18 years of age (Gest et al., 2014). In that same year in the United 
States, the FDA approved only Fluoxetine, with a “Black Box” warning, or a warning 
that calls attention to serious or life threatening risks, that said this was the only medicine 
for which there may be some benefit which counteracts some of the cons of taking the 
medication (Food and Drug Administration, 2012) (Gest et al., 2014). Despite the risks, 
there are few options for those who really need help and suffer with severe juvenile 
depression. Researchers say that strict bedtimes leading to a longer time asleep can be 
one factor in helping protect adolescents from depression (Gest et al., 2014). It can 
therefore be assumed that sleep duration, and practices that enhance this can then be 
protective against juvenile depression. Given its previous success with adult depression, 
chronotherapeutics has the potential to step up and fill this gap in care, offering another, 
safer alternative. There is not much available research focusing on adolescent depression 
and chronotherapeutics, however, the few studies that are currently available seem to 
offer promising results. One study found that bright light therapy was effective at 
reducing depressive symptoms in adolescents, but was hindered by its small sample size, 
while another was able to demonstrate an improvement when bright light therapy was 
given over two weeks—these subjects also maintained the reduction in depression 
symptoms for up to three weeks after the treatment (Gest et al., 2014). Another study 
found that a combination of bright light therapy and dawn simulation proved effective in 
battling seasonal affective disorder in children (Gest et al., 2014). With sleep deprivation, 
one study found a reduction of depressive symptoms for at least one day, and some of 
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those who were responsive maintained the remission for up to three to five days after 
treatment (Gest et al., 2014). This is a longer remission period than adults who utilize 
sleep deprivation (Gest et al., 2014). The most recent study from 2016 compared one 
night of sleep deprivation and bright light therapy versus bright light therapy alone in 13 
to 18 year olds with moderate to severe juvenile depression (Gest et al., 2016). Both 
groups showed reduced depressive symptoms and improved sleep quality, while the 
bright light only group was the only one to sustain the ameliorative effects up to two 
weeks after the treatment abated (Gest et al., 2016).  
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Mechanisms Behind Chronotherapy’s Effects on Mood Disorders 
 
While most of the mechanistic details of how chronotherapy has its ameliorating effects 
on mood disorders are still under study, researchers have been able to elucidate some 
details and offer some hypotheses.  
 
Sleep Deprivation Mechanism 
 
 Sleep deprivation has been shown to increase noradrenergic, dopaminergic and 
serotonergic neurotransmission, increase prefrontal cortex levels of glutamate and 
glutamine and increase levels of brain-derived neurotrophic factor (BDNF) to levels 
similar to those treated with electroshock therapy or prescription medication (Dopierala 
and Rybakowski, 2015). Sleep deprivation increases brain derived neurotrophic factor 
concentration by potentially increasing the amount of mRNA that eventually creates 
BDNF (Dopierala and Rybakowski, 2015). The effectiveness of sleep deprivation as a 
therapy can also be contingent on genetics. Patients who possess the homozygous long 
allele variant of the 5-HTTLPR serotonin transporter gene have increased mood 
improvement after sleep deprivation as compared to those who are heterozygous or 
homozygous for the short allele type (Dopierala and Rybakowski, 2015). In patients who 
experience alleviation of symptoms, there also appears to be a reboot of circadian rhythm 
genes that may have been malfunctioning (Dopierala and Rybakowski, 2015).  Those 
who have an improvement of symptoms after sleep deprivation often have increased 
expression of circadian rhythm genes like RORA, DEC2, and PER1 (Dopierala and 
Rybakowski, 2015). After total sleep deprivation, there was an increased amount of 
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mGluR5 glutamate receptors in healthy participants (Dopierala and Rybakowski, 2015). 
In depressed patients the amount of mGluR5 receptors is normally decreased, so there 
may be a potential antidepressant link between sleep deprivation and increased receptor 
density (Dopierala and Rybakowski, 2015). There are also studies that point to sleep 
deprivation stabilizing overactive portions of the brain for certain patients, leading to an 
improvement in the depressive symptoms. For people who responded well to sleep 
deprivation treatments, before therapy they showed large amounts of increased blood 
flow and glucose usage in the ventral anterior cingulate cortex and orbital medial 
prefrontal cortex. After therapy these areas went back to what would be considered a 
baseline healthy amount, while there was increased activity in the dorsolateral prefrontal 
cortex. (Dopierala and Rybakowski, 2015). In most patients with depression, there is a 
reduced activity in the dorsolateral prefrontal cortex (Dopierala and Rybakowski, 2015). 
These clinical findings were linked to an improvement in depression symptoms 
(Dopierala and Rybakowski, 2015). Sleep deprivation has also been shown to have an 
effect on the locus coeruleus nuclei (Dopierala and Rybakowski, 2015). On a more 
microscopic level, sleep deprivation has been shown to change catecholamine gene 
transcription (Dopierala and Rybakowski, 2015). Overall, sleep deprivation is believed to 
help restore the tendencies of focusing on negative events back to normal levels when 
combatting depression and there is decreased reactivity in the different corticolimbic 
pathways when presented with different emotionally and morally triggering stimuli 
(Benedetti et al., 2013). Sleep deprivation serves to effect changes in brain serotonergic, 
dopaminergic, noradrenergic, adenosine and glutamate levels and when there are greater 
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changes in the levels of these chemicals, greater changes in depressive symptoms occur 
(Benedetti et al., 2013). 
 
 Bright Light Therapy Mechanism 
 The exact mechanisms behind how bright light therapy works as an effective 
treatment for depression is not quite known, but there are a few proposed theories. One is 
that bright light therapy has an effect on serotonin and serotonin transporters (SERTs). 
Light exposure has been proven to increase levels of serum serotonin in major depressive 
disorder (Oldham and Ciraulo, 2014). Patients that were homozygous for the long variant 
of the SERT promoter region had a longer lasting break from depressive symptoms with 
bright light therapy than those with the short variant SERT promoter region (Oldham and 
Ciraulo, 2014). The American Psychiatric Association believes that serotonergic activity 
is the mechanism by which bright light therapy effectively combats major depressive 
disorder (Oldham and Ciraulo, 2014). Another theory focuses on bright light therapy and 
the relationship to melatonin. Those with seasonal affective disorder often have higher 
levels of melatonin present during the day compared with those without the disorder; 
however, upon successful bright light treatment this difference in melatonin levels 
disappears (Oldham and Ciraulo, 2014).  
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Blue Blocking Glasses Mechanism  
There is a hypothesis for why blue blocking glasses are effective in treating manic 
bipolar depression episodes (Henriksen et al., 2016). Normally, when the intrinsically 
photosensitive retinal ganglion cells are stimulated by blue light and begin activating the 
nonimage forming pathway, the locus coeruleus, a noradrenergic nucleus in the brain 
stem, is stimulated (Henriksen et al., 2016). The stimuli from these pathways are 
propagated to many different areas of the brain, and since the noradrenergic pathways 
have been activated once before, their neurons are more easily stimulated by other 
excitatory inputs later (Henriksen et al., 2016). The locus coeruleus also stimulates the 
hypothalamic-pituitary-adrenal (HPA) axis, and fMRI studies have shown that the effect 
blue light has when subjects are asked to perform an executive task is dependent on the 
phase of the circadian rhythm as well how much sleep the subject has had (Henriksen et 
al., 2016). In those with bipolar depression, the hypothalamic-pituitary-adrenal axis is 
dysfunctional and their circadian rhythms are irregular (Henriksen et al., 2016). There 
also seems to be a link between the manic symptoms being heightened by the excited 
state of the brain via the pathways and different structures that blue light and the 
subsequent locus coeruleus nuclei have stimulated (Henriksen et al., 2016). The blue light 
blocking subjects found a decrease in symptoms related to activation on the Young 
Mania Rating Scale before experiencing a decrease in the other items related to disturbed 
thoughts; this led researchers to believe that the main effect of blue blocking glasses is 
deactivation of certain brain regions (Henriksen et al., 2016). Once brain activation was 
under control, the rest of the manic bipolar depression symptoms quickly followed suit; 
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leading researchers to conclude that psychotic symptoms and altered thought processes 
may be effects of having increased activation (Henriksen et al., 2016) This also follows 
the order that manic episodes develop in; typically activation rises and then cognitive 
decline follows (Henriksen et al., 2016). It is the decrease in activation symptoms 
specifically that led researchers to believe that it is the reduction in brain stimulation via 
the intrinsically photosensitive retinal ganglion cells and locus coeruleus that lead to 
improvement, versus secondary effects that also may be present with blocking blue light 
like increased melatonin or a more regulated circadian rhythm (Henriksen et al., 2016). In 
those without bipolar depression, blue blocking glasses are thought to work by increasing 
the amplitude of light’s Zeitberger effect on circadian rhythms, versus changing the sleep 
phase (van der Lely et al., 2015). The greater difference there is in amplitude between 
light and nighttime signals helps lead to a stronger and multifocal synchronization of the 
body’s different circadian clocks, along with a better sleep pattern (van der Lely et al., 
2015). 
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Risks and Drawbacks of Chronotherapy Use 
 
While chronotherapeutic interventions seem relatively safe, there do exist some side 
effects and drawbacks that clinicians and patients should be aware of.  
 
Sleep Deprivation Drawbacks 
As mentioned above, one of the drawbacks of using sleep deprivation to treat 
depression is that the depressive symptoms often return once the patient resumes a 
normal sleep cycle (Dopierala and Rybakowski, 2015). Thus, any chronotherapy 
approach which utilizes either partial or total sleep deprivation should consider a dual or 
three-pronged approach, which involves bright light therapy, sleep phase advance and, in 
instances where it is helpful, pharmacological interventions. This increases the level of 
complication for the clinician administering the treatment and adds complexity for the 
patient, which may make the treatment more difficult to adhere to.  
 Any clinician seeking to utilize chronotherapeutic treatment options must be wary 
of using sleep deprivation on patients who exhibit psychotic symptoms. There may be 
enhanced psychotic episodes after sleep deprivation, especially in bipolar depressive 
patients, specifically those who have rapid cycling bipolar affective disorder (Dopierala 
and Rybakowski, 2015). Other side effects of sleep deprivation, besides feelings of 
somnolence, include an increased risk of epileptic seizure and headaches (Dopierala and 
Rybakowski, 2015). Sleep deprivation therapy is therefore not recommended for those 
with a history of epilepsy.  
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 Sleep deprivation can also increase the body’s inflammatory response. After 
treatment with sleep deprivation some patients can experience an increased concentration 
of interleukin 6 (IL-6) as well as increased levels of an antagonist for an interleukin1 
receptor (IL-1RA) (Dopierala and Rybakowski, 2015). Those suffering from depression 
often already have an elevated concentration of cytokines in their body, and increasing 
the inflammatory response is not a desired outcome.  
 In patients who do not experience a mood improvement after sleep deprivation, 
they often have a reduced expression of circadian rhythm genes as compared to before 
treatment (Dopierala and Rybakowski, 2015). Research is yet unclear as to whether they 
experience a subsequent worsening of symptoms following reduced gene expression. 
 
Bright Light Therapy Drawbacks 
Although largely efficacious, bright light therapy does have a few drawbacks. 
After bright light treatment is stopped, the depression symptoms can recur after a few 
days (Oldham and Ciraulo, 2014). Some side effects of bright light therapy include 
restlessness, eyestrain from looking at bright lights, queasiness, headaches and irregular 
menstrual cycles (Oldham and Ciraulo, 2014). For those who have eye disorders, they 
will need to check with an ophthalmologist before beginning treatment and as they 
continue the course, but so far, in long term studies of those with seasonal affective 
depression who use bright light therapy, no ocular issues have been reported (Wirz-
Justice et al., 2011). In those suffering from bipolar depression, there is a chance that 
bright light therapy may facilitate a rapid transition from a depressive episode into a 
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manic, hypomanic or mixed episode, however this risk is also present with selective 
serotonin reuptake inhibitors (Oldham and Ciraulo, 2014). In fact, using 
chronotherapeutics has a lower risk, with the strongest chronotherapy options reporting a 
risk of 10% for manic switches, while antidepressant medications can cause a switch in 
25% of those with bipolar depression (Wirz-Justice et al., 2011). When initially 
combining bright light therapy with antidepressant medications there has been an 
increase in new suicidal thoughts (Oldham and Ciraulo, 2014). From a feasibility 
perspective, despite proving itself as a potential treatment option in treating depression, 
bright light therapy is not often utilized to combat non-seasonal major depressive 
disorder; meaning physician knowledge and willingness to use this treatment is still an 
issue (Oldham and Ciraulo, 2014). Bright light therapy has a high up front cost when 
ordering the light device, and the cost of the device is not covered by Medicare (Oldham 
and Ciraulo, 2014). There is also no FDA standard to which the device must be built, and 
there is yet to be a general universal prescribing guideline for the treatment itself, besides 
a suggestion for 30 minutes in the morning between 2,500 to 10,000 lux (Oldham and 
Ciraulo, 2014) (Bartlett et al., 2013). Patients must also be committed to utilizing the 
treatment every day for the appropriate amount of time everyday, because as soon as they 
stop, the depressive symptoms can return; thus patient compliance is another factor to 
consider (Oldham and Ciraulo, 2014). 
Melatonin Drawbacks 
While possessing some usefulness, melatonin alone has not proven to be as useful as light 
therapy or sleep deprivation when treating seasonal affective depression or bipolar 
	 	
 51 
depression. This may be because of its short half-life (20-30 minutes), and melatonin’s 
effect may wear off before it can counteract any sleep phase advance or delay (Brown et 
al., 2018). A clinician must also be careful with the dosing of melatonin, as higher 
dosages do not equal a greater effect. While dosages of 0.025 mg or 0.5 mg might be 
helpful for the resynchronization of a blind patient, 10 mg fails to accomplish the same 
(Brown et al., 2018). Although melatonin is often classified as an anti-inflammatory 
substance, it can also be pro-inflammatory and pro-oxidant, and so caution must be taken 
in administering dosages that are greater than necessary (Brown et al., 2018). In 
rheumatoid arthritis melatonin has been implicated in provoking an enhanced flare-up 
(Brown et al., 2018). Clinicians should then be careful of prescribing melatonin in 
patients who suffer from autoimmune diseases, lest it aggravate existing conditions 
(Brown et al., 2018). Research suggests that the current recommendations of prescribing 
3.0 to 9.0 mg of melatonin for patients suffering from jetlag may need to be reexamined, 
and this dosage is also not approved for use in adolescents (Bartlett et al., 2013). 
Clinicians must also be wary of prescribing melatonergic medications; the recommended 
dosages of these medicines are often much higher than the ones necessary for naturally 
occurring melatonin and one in particular, agomelatine, while having mixed reviews for 
treating depression and insomnia, has been implicated in causing hepatotoxicity in some 
patients while carrying contraindications for those with liver pathologies (Brown et al., 
2018). There is also no evidence that these synthetic compounds, although possessing a 
longer half-life than melatonin, act any better at inducing sleep as melatonin in low 
dosages (Brown et al., 2018). 
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General Limitations of Chronotherapy 
 One of the largest limitations of making chronotherapy more widespread is that 
there remains limited access to circadian rhythm tracking technology outside of research 
settings, and most clinicians are not well versed in the different aspects of measuring 
healthy circadian rhythms or how to analyze and interpret the data (McKenna et al., 
2018). In order to fix an off-schedule circadian rhythm, the clinicians must first be able to 
identify what an irregular rhythm looks like, especially when compared to a baseline 
chronotype, in order for the clinician to determine whether or not the sleep phase is 
advanced or delayed to accurately correct for it (Brown et al., 2018).  
 For a small percentage of mood disorder patients, chronotherapeutics will not 
have an effect. In some patients, neither light therapy nor melatonin supplementation will 
help (Brown et al., 2018). These patients often have advanced deterioration of the 
suprachiasmatic nuclei or its subsequent neuronal pathways (Brown et al., 2018). This is 
most often the case in patients with advanced stage Alzheimer’s, who exhibit largely 
decreased levels of melatonin and highly dysregulated circadian rhythms (Brown et al., 
2018). Other theoretical cases in which patients may be resistant to light and melatonin 
therapy include those who, at birth, have severe mutations in genes responsible for 
circadian timing, or severe mutations in the genes that code for melatonin receptors 
(Brown et al., 2018). However, this is a much more rare subset of the general population 
(Brown et al., 2018). 
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CONCLUSIONS 
 
Although there are some drawbacks and side effect risks in utilizing chronotherapy to 
treat mood disorders, overall these are largely outweighed by the numerous benefits these 
treatments provide to patients. Sleep deprivation, bright light therapy, blue blocking 
glasses and targeted combinations of different chronotherapy approaches have been 
proven to counteract the symptoms of mood disorders in a manner that is faster, safer and 
more efficacious than traditional and conventional therapies. There is relief for patients 
who may have been previously resistant to other treatment types, and chronotherapy’s 
potential to be used as a tool against depression in pregnant and post-partum women, 
juvenile depression and in its quick action in reducing suicidal thoughts are of particular 
and unique value of this treatment modality. The combination of chronotherapeutics and 
conventional treatments has also proven to be especially effective in achieving a 
reduction in symptoms and potential remission of symptoms. The side effects of 
chronotherapeutics are small and much less harmful than those of traditional approaches 
and in some approaches, like light therapy, significant barriers to access are reduced that 
may have potentially hindered someone from seeking treatment before. Therefore, 
chronotherapeutics should be utilized as an adjunct therapy for the treatment of mood 
disorders. 
 There is still much research to be done which can help with the implementation of 
this treatment on a wider scale. Researchers can determine what the effects are of 
administering bright light therapy at different points during the day, different lengths of 
time, light wavelengths, and different intensities have on the efficacy of the treatment 
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(Oldham and Ciraulo, 2014). This can help guide future prescription suggestions 
(Oldham and Ciraulo, 2014). More random clinical trials on the effects of 
chronotherapeutics in treating juvenile depression are needed. Additionally, more 
research is needed to ascertain the proper dosing of melatonin, specifically using 
immediate acting low dosages, as past studies have been hindered by large dosages 
(Brown et al., 2018).  
Another potential area of research for scientists includes an easy hospital and 
clinician-friendly way of plotting and monitoring an individual’s circadian rhythm 
(McKenna et al., 2018). Identifying a patient’s chronotype early on can give the clinician 
an idea of whether or not their particular type predisposes them to certain mood disorders 
(Berg et al., 2018). If advances in plotting and monitoring individual rhythms were made, 
certain therapies and medicines could be better tailored and suited to the patient’s 
particular chronotype and circadian rhythm pattern. As mentioned above, 
chronopharmacology, or administering certain drugs at specific times, is a new area of 
research, which is showing some promise (McKenna et al., 2018). Clinicians could then 
administer prescription medicines accordingly, to either enhance their effects or adjust for 
medicines that change or affect the body’s circadian rhythm (McKenna et al., 2018). 
Medicines themselves could be tailor-made to target the genes that coordinate the body 
clock, and such research has already begun on man-made ligands to bind to Rev-Erbα 
receptors (McKenna et al., 2018). In the future, to better assess whether or not a subtype 
of a mood disorder may be more responsive to treatment, clinicians can also attempt to 
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detect circadian rhythm gene variants by taking a blood sample and examining the DNA 
in peripheral blood mononuclear cells (Brown et al., 2018). 
 On a cellular level, many questions still remain before scientists can claim a true, 
full and complete understanding of how the body regulates its internal circadian clocks. 
Scientists still wish to know how genes that influence circadian rhythms control and 
enhance or surpress the transcription process and how the suprachiasmatic nuclei is able 
to influence the circadian rhythms of various peripheral tissues at a cellular level 
(Hastings et al., 2008) It is still to be determined how the circadian dependent electrical 
firing rate in the suprachiasmatic nuclei cooperates with the existing transcriptional 
mechanisms and scientists are still trying to determine how conductance is controlled by 
a rhythmic timed potential (Hastings et al., 2008).  Furthermore, it is still unknown how 
changes in neuron firing and the secretion of different concentrations of neuropeptides 
help signal timing that corresponds with the earth’s circadian rhythm (Hastings et al., 
2008). Examining the science behind chronotherapy is a relatively new and unexplored 
field that is ripe with possibilities for new research, findings and contributions to the 
scientific community.  
 In the meantime, there are steps that clinicians can take to implement 
chronotherapy in their practice. The first step is being aware of and prescribing 
chronotherapeutic interventions to patients who need it, who would seem to benefit from 
it and those who are not contraindicated otherwise. Clinicians who are aware of the 
importance of maintaining the body’s natural circadian rhythms, especially as it is linked 
to maintaining the homeostasis of so many biological systems, can refer patients to 
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appropriate interventions, even if they themselves are not yet fully equipped (McKenna et 
al., 2018). Some of the steps that hospitals can implement to improve circadian rhythm 
synchronization while in the hospital, and especially after a serious illness when rhythms 
are vulnerable to dysregulation include: having brighter lights and/or more natural light 
exposure during the day, minimizing light and noise pollution during the evening, 
limiting feeding and exercise to the daytime and minimizing the medical interventions in 
the evening and nighttime (McKenna et al., 2018). Steps can also be taken to try to avoid 
to the use of sedatives as much as is feasible, to incorporate activity into the patient’s 
recovery as early as possible and to administer medicines at the times at which they are 
the most chronotherapeutically optimal (McKenna et al., 2018). In the ICU there are 
many elements that can contribute to fractured sleep and disrupted circadian rhythms. 
There is often a great deal of noise, interruptions from the hospital staff whilst the patient 
is sleeping, pain, stress, prescription medications and continuous exposure to electrical 
lights, to name a few (Chan et al., 2012). Thankfully, small changes there can also make 
a difference in improving and resetting circadian rhythms. The use of eye masks and ear 
plugs in the evening, to decrease light exposure and noise respectively, in ICU settings 
has been shown to increase circulating melatonin levels (McKenna et al., 2018). 
  Chronotherapy shows promise as an effective treatment for mood disorders and 
more efforts should be made to implement its use as an established therapy. As rates of 
depression and other mood disorders rise in society, medical professionals will need to 
come up with other novel and more effective ways to tackle the challenge it presents. 
Research has found that those with a high risk of depression face the greatest increase in 
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medical costs yearly, more so than if they had diabetes, cardiovascular disease, were 
smoking or were obese, with health care costs rising almost 50%, or $2000 a year per 
person for those that fall under that category (Oldham and Ciraulo, 2014). Additionally, 
one of the potential and most serious consequences of suffering with depression is 
suicide. For 15-29 year olds, suicide is the second leading cause of death and suicide is 
the cause of death for 800,000 people every year, or 1 person every 40 seconds (World 
Health Organization, 2018). Those with bipolar depression have the highest risk of 
committing suicide in those with psychiatric diseases, with 30% of sufferers attempting 
suicide and 20% or one in five sufferers succeeding in killing themselves (Benedetti et 
al., 2013)(Henriksen et al., 2016). The World Health Organization has recognized the 
need to tackle mental health challenges and address the multi-level and far reaching 
impact these diseases can have, declaring a one year campaign on depression in 2017 
(World Health Organization, 2018). With diseases that are as prevalent and impactful as 
this, scientists must continue to strive to develop treatments that work quickly, are 
effective, able to be widely implemented, cost effective, and help prevent relapses 
(Oldham and Ciraulo, 2014). The treatments found can literally save lives.  
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